Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability

Abstract

Background and Aim There is little published research to examine the best approach to the management of Helicobacter pylori in Myanmar. This study aimed to determine the relative efficacy and tolerability of sequential eradication therapy compared to Myanmar's current recommendation of a concomitant four drug regimen. Methods Patients were screened for H. pylori using monoclonal Stool Antigen Testing (SAT). Those testing positive were randomized 1:1 to receive receive Myanmar's first‐line regimen of 14 days of concomitant rabeprazole, clarithromycin, amoxycillin and tinidazole (140 pills, cost US$23) or 10 days of sequential rabeprazole, clarithromycin, amoxycillin and tinidazole (60 pills, cost US$10). Adherence and adverse effects were recorded, and the efficacy of the regimens assessed with repeat SAT. Results Of the 1011 patients screened for H. pylori infection, 313 (31%) tested positive. There was no statistical difference in the cure rates of the two regimens in either intention‐to‐treat: 128/157 (82%; 95% confidence interval (CI): 75–87%) receiving sequential therapy versus 123/156 (79%; 95% CI: 72–85%) receiving concomitant therapy (P = 0.55) or per‐protocol analysis: 125/131 (95%; 95% CI: 90–98) receiving sequential therapy versus 121/130 (93%; 95% CI: 87–96) receiving concomitant therapy (P = 0.42). Side effects of therapy were reported in 54/157 (47%) patients taking sequential therapy compared with 62/156 (53%) taking concomitant therapy, but this difference did not reach statistical significance (P = 0.33). Conclusions In this high‐burden, resource‐poor setting, less expensive sequential therapy was as effective and as well tolerated as the currently recommended concomitant four drug regimen for eradication of H. pylori.

Comparison of sequential therapy with concomitant therapy in first-line treatment of Helicobacter pylori: an updated meta-analysis

“…Via a full-test review, 12 studies were obsolete for specific reasons. Finally, only 24 studies [10–33] were incorporated. Additional details about the study selection could be found in .…”

The impact of gender and the social determinants of health on the clinical course of people living with HIV in Myanmar: an observational study

“…This suggests that once patients in Myanmar are able to access ART they usually do well. This may be explained by the fact that all HIV care in Myanmar is free of charge, that there is increasing access to contemporary ART (over 80% of this cohort received a dolutegravir-based regimen) and that medication adherence is generally excellent [ 3 , 19 ]. The Global Fund to fight AIDS, Tuberculosis and Malaria provides funding for peer support workers who support HIV care, provide counselling and psychosocial support and who play a crucial role in ensuring retention in care [ 3 ].…”

The status and progress of first-line treatment against Helicobacter pylori infection: a review

“…According to PP analysis, their eradication rates were 95% and 93%, respectively, and according to ITT analysis results, they were 79% and 82.5%, respectively. 27 Similarly, in Korea, a multicenter RCT involving 1141 people showed that in first-line treatment, the eradication rate of the 10-day CT regimen was significantly higher than that of the 7-day triple therapy regimen (ITT, 81.2% versus 63.9%; PP, 90.6% versus 71.4%); the eradication rate of the 10-day ST regimen was also better than that of the 7-day triple therapy regimen (ITT, 76.3% versus 63.9%; PP, 85.0% versus 71.4%), and there was no significant difference in adverse reactions among the three regimens. 28 In Egypt, a prospective study not only compared the efficacy between ST and standard triple treatment but also estimated the optimal duration of ST. Studies have shown that ST is superior to triple therapy, especially when ST lasts for 14 days (96.7% versus 90.7% versus 63.3%).…”